Tumour hypoxia is associated with aggressive disease and treatment resistance in prostate cancer ([@bib29]; [@bib42]). Current clinicopathological markers are insufficient to identify patients at risk of treatment failure ([@bib10]; [@bib33]), and a hypoxia biomarker would be of value for the clinical decision making. The exogenous hypoxia marker pimonidazole is a 2-nitroimidazole compound, which forms covalent bonds with cellular macromolecules at oxygen levels below 1.3% ([@bib16]) and visualises poorly oxygenated regions in histological sections from tumours ([@bib21]). Only two studies have reported on the marker in prostate cancer ([@bib5]; [@bib18]). Increased pimonidazole staining was found in tumours with high Gleason score ([@bib5]). Although pimonidazole seems not to be feasible for routine use owing to difficulties in assay standardisation, this encourages further exploration of the marker and methods derived from it.

Molecular biomarkers such as gene signatures have shown promising results in risk stratification of prostate cancer patients ([@bib33]), but the current knowledge of gene expression in hypoxic prostate tumours is scarce. By combined analysis of global expression profiles and pimonidazole data, a comprehensive picture of the transcriptional programme in pimonidazole-positive tumours can be achieved. This would increase our understanding of the hypoxic phenotype and would be of value in the development of a hypoxia biomarker. A major challenge in the use of biopsy-based biomarkers in prostate cancer is, however, the multifocality of the disease and pronounced intratumour heterogeneity in molecular abnormalities, which pose the need of sampling standardisation ([@bib14]). Recent advancements in image-guided technology facilitate sampling from the most aggressive sub-population within the tumours, that is, the index tumour (Sonn *et al*, 2013), which may solve this problem.

The present study was performed to explore the hypoxic phenotype associated with pimonidazole staining in prostate cancer. Based on pairwise gene expression and pimonidazole data, we determined the transcriptional programme of pimonidazole-positive tumours and constructed a signature with 32 essential genes. The investigation was based on a prostatectomy cohort, where correct prediction of index tumour by image guidance could be verified from the histopathology of the surgical specimen. We further explored the underlying biology of the signature and its ability to depict an aggressive tumour phenotype in independent cohorts.

Patients and methods
====================

Investigation cohort
--------------------

Fifty-two patients referred for robot-assisted laparoscopic radical prostatectomy (RALP) from October 2011 to July 2012 at Oslo University Hospital, and recruited to our ongoing FuncProst-study (NCT01464216) ([Supplementary Table S1](#sup1){ref-type="supplementary-material"}) were used as investigation cohort to find pimonidazole-associated genes. All patients had intermediate or high-risk disease according to the D\'Amico classification ([@bib9]). Patients who received hormonal therapy or radiotherapy before surgery were excluded. Written informed consent was obtained from all patients. The study was approved by the regional ethics committee and the protocol review committee of our institution.

The patients underwent preoperative, multiparametric magnetic resonance imaging (MRI) using a 1.5 T GE Discovery 450 (General Electric, Waukesha, WI, USA) magnet and phased array coils. The MRI protocol consisted of morphologic, T1- and T2-weighted (T1W/T2W), and functional, diffusion-weighted and dynamic contrast-enhanced (DW/DCE), sequences covering the pelvis and the lower abdomen. The protocol and image interpretation were in accordance with the European Society of Urogenital Radiology (ESUR) 2012 Guidelines ([@bib2]). Lymph node status was determined based on node diameter and morphology in isotropic 1 mm T2W images.

Forty-three patients received 500 mg pimonidazole hydrochloride (Hypoxyprobe Inc., Burlington, MA, USA) per m^2^ body surface in 100 ml 0.9% NaCl intravenously over 20 min the day before RALP. The maximum dose was 1000 mg, except for two patients who received 1025 and 1150 mg. The half-time of pimonidazole in blood is 5.1 h (<http://www.hypoxyprobe.com>). No patients experienced any side effects during or after the infusion. For the remaining nine patients in the cohort, pimonidazole infusion was not possible due to either anaphylactoid reaction to MR contrast agent or absence of study personnel, or correct quantification of pimonidazole staining was not possible due to postponing of surgery.

A three-armed robotic DaVinci system (Intuitive Surgical, Sunnyvale, CA, USA) was used to perform RALP ([@bib1]). Pelvic lymph node dissection was generally performed in high-risk patients or when preoperative MRI had raised suspicion of lymph node metastasis. Lymph node status was thus determined either by pathological examination of lymph nodes or considered negative if preoperative MRI was negative and serum level of prostate-specific antigen (PSA) 6 weeks after prostatectomy was undetectable ([Supplementary Table S1](#sup1){ref-type="supplementary-material"}). Time from pimonidazole infusion to complete dissection of the prostate was recorded. The prostate was placed on ice immediately after RALP and transported to the pathology department.

Index tumour biopsies
---------------------

Index tumour was predicted in MR images based on a combination of low signal intensity (SI) in T2W and T1W images, low apparent diffusion coefficient (ADC) and high SI in heavily DW images, and rapid wash-in and wash-out in DCE images ([Figure 1A and B](#fig1){ref-type="fig"}). By guidance from palpation of the prostate, preoperative biopsies and multiparametric MRI, the prostate was cut horizontally into two halves where the assumed index tumour was located. Two punch biopsies, 6 mm in diameter, were taken from the tumour, immediately snap frozen in liquid nitrogen and stored at −80 °C ([Figure 1C](#fig1){ref-type="fig"}). The prostate specimens were fixed in 10% buffered formalin for at least 48 h, and grossing was performed according to a standardised protocol ([@bib38]). Histopathological staging and grading were performed according to the TNM classification ([@bib36]) and a modified Gleason score system ([@bib12]). In case of multifocal tumour, index lesion was defined as, in descending order, pathologic T stage, Gleason score and tumour size, as discussed in [@bib44]. By review of the pathology reports, one or both of the punch biopsies were verified to be from index tumour in 46 (88%) of the patients, who were included in further analyses. Out of these, 39 patients had received pimonidazole. The biopsy with highest Gleason score within the index tumour was selected for gene expression and immunohistochemistry ([Figure 1D](#fig1){ref-type="fig"}), for which all had at least 75% malignant glands and \<50% stroma in haematoxylin and eosin (HE)-stained sections ([Figure 1E](#fig1){ref-type="fig"}). Time from complete dissection of the prostate during RALP to snap-freezing of biopsies was recorded and denoted ischaemia time.

Immunohistochemistry
--------------------

Immunohistochemistry was performed with monoclonal mouse antibodies for pimonidazole (1 : 50; Hypoxyprobe Inc.) on 39 tumours and Ki67 (1 : 75, MIB-1; Dako, Glostrup, Denmark) on 46 tumours using standard protocols extensively used at our institution. Pimonidazole antibody concentration was titrated to achieve high dynamic in staining intensity across the tumours. After thawing, sections were fixed in formalin for 15 min and rinsed in running water. Antigen retrieval was performed through boiling in citrate buffer (pH 6.0) in a microwave oven for 15 min. Endogenous tissue peroxidase was quenched with hydrogen peroxide before incubation with antibodies for 30 min in room temperature. For visualisation, Envision system (Dako) was used, followed by counterstaining with haematoxylin, dehydration and mounting. One of the positive tumours was selected as a biological positive control and included in each run, ensuring satisfactory staining reproducibility. As a negative control, the primary antibodies were replaced with mouse myeloma proteins of equal subclasses and immunoglobulin concentrations. In addition, a patient who had received no pimonidazole served as a biological negative control for pimonidazole staining. None of the negative controls showed any reactivity.

The staining pattern of the malignant glands was evaluated blinded to gene expression and other immunohistochemistry data. Pimonidazole scoring was performed independently by two study pathologists (LV and AKL). Fractions of nuclear and moderate to strong cytoplasmic staining were determined separately and given immunoscores from 0 to 5 (0: 0% 1: 1--10% 2: 11--50% 3: 51--90% 4: 91--100% and 5: 100%). It was a good agreement between the data of the two pathologists (*κ=*0.80; *P*\<0.0001; [Supplementary Figure S1](#sup1){ref-type="supplementary-material"}), and in cases of disagreement, a consensus value was determined. The average value of cytoplasmic and nuclear immunoscore was used as the pimonidazole-positive fraction. Ki67 staining was scored by one of the pathologist (LV) in hot-spots identified at low magnification. At least 500 tumour cells (median 610, range 501--963 cells) were evaluated in printed pictures at × 400 magnification. Ki67 labelling index was calculated as the number of positive nuclei divided by the total number of nuclei.

Cell lines and hypoxia treatment
--------------------------------

The human prostate cancer cell lines 22Rv1, LNCaP, PC-3 and DU 145 were used to generate prostate cancer-specific sets of hypoxia-responsive genes. The cell lines were cultured, routinely tested for mycoplasma and identity confirmed by short tandem repeat profiling as described by [@bib32]. Hypoxia treatment (0.2% O~2~, 95% N~2~, 5% CO~2~) of exponentially growing cells at 60--70% cell confluence was carried out in an *In Vivo*~2~ 200 chamber (Ruskinn Technology, Brigend, UK) for 24 h at 37 °C. Cells were plated and incubated for 2 days, following medium replacement and hypoxia exposure. Normoxia samples (95% air, 5% CO~2~) were run in parallel.

Gene expression profiles
------------------------

Gene expression profiles from fresh-frozen biopsy sections of 46 tumours and normoxia- and hypoxia-treated cell lines were derived using Illumina bead arrays HT-12 v4 (Illumina Inc., San Diego, CA, USA) with ∼47 300 transcripts, as described by [@bib17]. Total RNA was isolated using the RNeasy MiniKit (Qiagen, Hilden, Germany). RNA quality control was performed with Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). cRNA was synthesised, labelled and hybridised to the arrays. Signal extraction and quantile normalisation were carried out using the software provided by the manufacturer (Illumina Inc.). Log-transformed data were used in all analyses. The data have been deposited to the Gene Expression Omnibus (GEO) repository (GSE55935).

Computational analysis of gene expression
-----------------------------------------

Gene expression profiles were combined with pimonidazole data in a two-step procedure described previously ([@bib17]). First, an explorative, unsupervised analysis was performed. The investigation cohort was split into a pimonidazole-positive and -negative group according to an immunoscore of \<2 (*n*=21) or ⩾2 (*n*=18), and the Linear Models for Microarray Data software was applied to find genes differentially expressed between the groups. A nominal *P*-value of 0.05 was used as cutoff, resulting in an appropriate number of about 1000 genes. Biological processes enriched in the pimonidazole-positive group were analysed using the DAVID gene ontology (GO) software ([@bib19]), where a false discovery rate of \<10% (*q*\<0.1) was considered to be significant.

Second, a supervised gene set enrichment analysis was performed with 21 gene sets covering the significant biological processes from the GO analysis, using the Significance Analysis of Microarrays for Gene Sets (SAM-GS) software, which is based on the moderated t-statistics in SAM ([@bib11]). All gene sets were collected from the Molecular Signatures Database except a prostate cancer-specific hypoxia gene set constructed in this work, two hypoxia gene sets constructed in head and neck ([@bib41]) and cervical cancer ([@bib17]) and two target gene sets of the hypoxia-inducible factor 1 (HIF1) ([@bib32]) and androgen receptor (AR) ([@bib27]), respectively. The prostate cancer-specific hypoxia gene set was generated from the expression data of four prostate cancer cell lines and included genes with more than two-fold upregulation under hypoxia in at least two cell lines ([Supplementary Table S2](#sup1){ref-type="supplementary-material"}).

Validation cohorts
------------------

To validate results from the investigation cohort, two prostate cancer gene expression data sets in GEO with clinical information related to disease aggressiveness were applied (GSE32571 and GSE16560). In GSE32571, Illumina gene expression of about 48 000 transcripts was available for 59 patients, who were grouped according to a Gleason score ⩽7a or ⩾7b ([@bib23]). The Gleason score ranged from 5 to 10, where the majority of the patients had a score of 7a (*n*=28) or 7b and above (*n*=27). GSE16560 contained data of 281 patients in a Swedish watchful waiting cohort, including expression of 6100 genes from the cDNA-mediated annealing, selection, ligation and extension (DASL) platform and up to 30 years follow-up for survival ([@bib34]). The patients had either died from prostate cancer or survived more than 10 years without metastases.

Statistics
----------

Spearman\'s rank correlation and Mann--Whitney *U*-tests were applied on immunohistochemistry data, and Student\'s *t*-test was used on continuous data. Associations between categorical data were analysed by *χ*^2^ test. Kaplan--Meier curves were compared with log-rank test. Multivariate regression analysis was performed using Cox proportional hazards model. Cohen\'s kappa (*κ*) was used to evaluate the agreement between immunoscores obtained from two different pathologists. PASW Statistics 18 for Windows (SPSS Inc., Chicago, IL, USA) was used with a significance level of 0.05, unless otherwise specified.

Results
=======

Pimonidazole staining in relation to tumour aggressiveness and gene expression
------------------------------------------------------------------------------

The pimonidazole staining pattern differed considerably among tumours ([Figure 2A and B](#fig2){ref-type="fig"}). Median immunoscore was 2, and 18 cases (46%) had an immunoscore of 2 or higher, implying a pimonidazole-positive fraction above 10%. The immunoscore was significantly higher for tumours at a high clinical stage (*P*=0.019; [Figure 2C](#fig2){ref-type="fig"}) and with lymph node metastasis (*P*=0.033; [Figure 2D](#fig2){ref-type="fig"}), suggesting an association between pimonidazole staining and tumour aggressiveness. Staining was not correlated with time from pimonidazole infusion to complete dissection of the prostate ([Supplementary Figure S2A](#sup1){ref-type="supplementary-material"}), blood PSA level or ischaemia time (data not shown).

To obtain a general picture of the biology of pimonidazole-positive tumours, all differentially expressed genes between pimonidazole-positive and -negative tumours were included in an unsupervised GO analysis. Three major, significant biological processes were identified based on the 1046 genes that were upregulated in pimonidazole-positive tumours: cell cycle, translation and cellular response to stress, including the subgroups DNA repair and response to DNA damage stimulus ([Supplementary Table S3](#sup1){ref-type="supplementary-material"}). A similar analysis of 862 downregulated genes identified only the process muscle system, whereas analysis of up- and downregulated genes combined showed no significant processes.

To address specifically all likely phenotypes of the pimonidazole-positive tumours, we used a supervised gene set analysis based on all genes on the array and 21 gene sets representing the significant biological processes from the GO analysis. Our prostate cancer-specific hypoxia gene set ([Supplementary Table S2](#sup1){ref-type="supplementary-material"}), six published hypoxia gene sets ([@bib28]; [@bib48]; [@bib3]; [@bib41]; [@bib17]; [@bib13]) and two sets of HIF1 and AR targets ([@bib27]; [@bib32]) were included to obtain a wide coverage of the hypoxia phenotype. To cover the cell cycle process, the reactome cell cycle checkpoint pathway and two published proliferation gene sets ([@bib7]; [@bib39]) were applied. We further used the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway for protein processing in endoplasmic reticulum to represent translation and eight sets of genes in various DNA repair pathways from the KEGG and GO databases to cover cellular response to stress and its subgroups.

The two proliferation gene sets showed the strongest association with pimonidazole immunoscore, followed by two DNA repair gene sets and the prostate-specific hypoxia gene set ([Table 1](#tbl1){ref-type="table"}). These five gene sets covered all significant biological processes from the GO analysis ([Supplementary Table S3](#sup1){ref-type="supplementary-material"}). Expression of genes in proliferation, repair and hypoxia response therefore seemed to pose a major contribution to the transcriptional programme reflected by pimonidazole staining.

Construction of a pimonidazole gene signature
---------------------------------------------

To find essential genes reflected by pimonidazole staining, we selected the five most significant gene sets covering the three phenotypes proliferation, repair and hypoxia response ([Table 1](#tbl1){ref-type="table"}), and extracted the 32 genes with a positive correlation to pimonidazole immunoscore (*P*\<0.05; [Table 2](#tbl2){ref-type="table"}). Negatively correlated genes were few (four in proliferation, one in repair, two in hypoxia response) and not included owing to the lack of significance for downregulated genes in the GO analysis. Several of the signature genes were direct HIF1 or AR targets ([@bib27]; [@bib17]; [@bib49]; [@bib15]; [@bib32]), suggesting that both the HIF1 and AR pathways were important parts of the transcriptional programme and activated in pimonidazole-positive tumours.

To confirm that the gene signature sufficiently reflected pimonidazole staining, unsupervised hierarchical clustering of the investigation cohort based on the 32 signature genes was performed. This produced two clusters, for which the cluster with high expression had higher frequency of pimonidazole-positive tumours (*P*=0.017; [Figure 3A](#fig3){ref-type="fig"}) and increased immunoscore (*P*=0.002; data not shown). We further calculated a pimonidazole gene score for each tumour by averaging the median-centred, log-transformed expression levels of the genes, to achieve a measure of the signature that could be compared in other cohorts. The gene score was higher for pimonidazole-positive tumours (*P*\<0.001; data not shown) and in patients with high clinical stage (*P*=0.031 and *P*=0.002 for cT3 *vs* cT2 and cT1, respectively; [Figure 3B](#fig3){ref-type="fig"}) and lymph node metastasis (*P*=0.001; [Figure 3C](#fig3){ref-type="fig"}). A correlation between gene score and Gleason score in the surgical specimens was also observed (*P*=0.033; data not shown). There was no relationship between the signature and ischaemia time ([Supplementary Figures S2B and C](#sup1){ref-type="supplementary-material"}), time from pimonidazole infusion to complete dissection of the prostate or blood PSA level (data not shown). The gene signature therefore seemed to satisfactorily represent pimonidazole staining, including its relationship to aggressiveness in the investigation cohort.

Pimonidazole gene signature in relation to Ki67 labelling index
---------------------------------------------------------------

The contribution of proliferation genes to the transcriptional programme of pimonidazole-positive tumours ([Table 1](#tbl1){ref-type="table"}) suggested increased proliferation activity. To validate this, the pimonidazole gene signature was analysed against the Ki67 proliferation marker. A significant positive correlation (*P*\<0.05) between gene expression and Ki67 labelling index was found for 14 signature genes, including eight proliferation genes, all three DNA repair genes and three hypoxia response genes, whereas no genes showed a significant negative correlation ([Table 2](#tbl2){ref-type="table"}). A significant correlation was also found for the gene score (*P*=0.001; [Figure 4A](#fig4){ref-type="fig"}). Moreover, Ki67 staining was often observed in pimonidazole-positive regions within tumours ([Figure 4B](#fig4){ref-type="fig"}). The increased proliferation associated with pimonidazole staining, as suggested from the gene data, was therefore confirmed. However, relatively high Ki67 labelling index was also seen in some tumours with low gene score ([Figure 4A](#fig4){ref-type="fig"}), and the difference in labelling index between pimonidazole-positive and -negative tumours was not significant but only a tendency was observed (*P*=0.17; data not shown). These observations support the contribution of other features covered by the gene signature, that is, DNA repair and hypoxia response, in addition to increased proliferation.

Validation of the pimonidazole gene signature in independent cohorts
--------------------------------------------------------------------

To validate the relationship between the pimonidazole gene signature and aggressiveness, we first investigated its association with Gleason score in the GSE32571 cohort, where all 32 signature genes were available. A significantly higher gene score was seen in the high Gleason group, as compared with the low one (*P*=0.002; [Figure 5A](#fig5){ref-type="fig"}). In the second validation cohort (GSE16560), only 19 signature genes were present, and we first confirmed that the gene score based on this subgroup of genes sufficiently reflected pimonidazole staining in the investigation cohort ([Supplementary Figure S3](#sup1){ref-type="supplementary-material"}). Thereafter, a significant relationship between the gene score and outcome was demonstrated in the GSE16560 cohort, both in log-rank test (*P*\<0.001; [Figure 5B](#fig5){ref-type="fig"}) and as a continuous variable in Cox univariate analysis (*P*\<0.001; [Table 3](#tbl3){ref-type="table"}). The relationships to aggressiveness were also seen for both validation cohorts when the patients were clustered based on the signature genes (data not shown). The two validation experiments therefore confirmed a relationship between the pimonidazole gene signature and tumour aggressiveness.

To assess the importance of the pimonidazole gene signature corrected for available clinicopathological markers, a multivariate Cox analysis was carried out on the GSE16560 cohort. The signature showed prognostic significance independent of the other markers (*P*\<0.004; [Table 3](#tbl3){ref-type="table"}).

Discussion
==========

We have performed an integrative analysis of global gene expression and pimonidazole staining in prostate cancer. Pimonidazole staining visualises cumulative hypoxia over the time period from infusion to snap-freezing of biopsies, provided that pimonidazole is still available in the tissue for binding. Systematic recording of time from infusion to surgery and from surgery to snap-freezing of biopsies showed that these parameters had no significant influence on our results, most probably because they differed little across the patients or because only minor pimonidazole was available in the tumour at the time of surgery. The staining differences therefore seemed to reliably represent differences in pretreatment hypoxia. The staining pattern reflected a transcriptional programme activated by proliferation, DNA repair and hypoxia and included a gene signature associated with aggressive disease in two independent patient cohorts, pointing to signalling pathways that may promote tumour progression. We demonstrated that index tumour could be successfully identified by guidance from multiparametric MRI, enabling standardised sampling of pretreatment biopsies to assess the signature. Our work provides novel insight into the molecular background of the hypoxic phenotype reflected by pimonidazole staining, encouraging studies to clarify the potential of the gene signature in the decision making of patients with prostate cancer.

Gene expression associated with increased proliferation posed a major part of the transcriptional programme reflected by pimonidazole staining. This conclusion was based on results from both GO and gene set analyses, where the cell cycle process and proliferation gene sets were the most significant ones, respectively, and by the observed correlation between gene expression and Ki67 labelling index. Also, the upregulation of DNA repair genes could reflect increased proliferation, being a consequence of elevated replication stress ([@bib8]). In accordance with our results, expression of the hypoxia-inducible lactate dehydrogenase 5 isoenzyme has been found to be elevated in the most proliferative prostate tumours ([@bib22]), supporting a positive relationship between proliferation and hypoxia in this disease.

The mechanisms underlying high proliferation capacity of pimonidazole-positive tumours is not clear. Upregulation of HIF1 and AR targets was part of the transcriptional programme reflected by pimonidazole staining. Similar to HIF1, AR is activated under hypoxia and promotes cell survival, metabolism and proliferation ([@bib30]; [@bib31]; [@bib25]). Although severe hypoxia may induce cell cycle arrest and apoptosis, the oxygen levels reflected by pimonidazole staining seemed to be sufficiently high to allow proliferation, maintaining metabolic activity and oxygen consumption. A similar conclusion was drawn in a pimonidazole study on colorectal cancer metastases ([@bib45]), but seemed not to be valid for head and neck cancer ([@bib47]), indicating that this finding is tumour type-dependent. Alternatively, the high proliferation capacity and overlap between pimonidazole and Ki67 staining may be due to reoxygenation of hypoxic regions after irreversible pimonidazole binding.

Extraction of essential genes in the transcriptional programme resulted in a signature associated with aggressive features, including poor clinical outcome. The signature seemed to capture both elevated proliferation and hypoxia, which are two known aggressive prostate cancer phenotypes ([@bib29]; [@bib42]; [@bib46]). A gene set reflecting proliferation and hypoxia-related tissue remodelling was recently found to have strong association with survival of prostate cancer patients, as compared with a proliferation or hypoxia-related gene set alone ([@bib26]). Pimonidazole staining possibly reflects oxygen levels that promote such an aggressive phenotype by covering both proliferation and hypoxia response. Moreover, our signature might be refined to become a marker of this aggressive hypoxic phenotype.

Little is known about how the individual signature genes influence prostate cancer progression. Upregulation of some genes or their encoded protein has been associated with aggressive disease (*BIRC5*, *MCM2* and *TRIP13*) ([@bib35]; [@bib24]; [@bib40]). Moreover, SCD has been shown to enhance AR transcriptional activity and thereby promote proliferation of prostate cancer cells ([@bib20]), FOXM1 seems to have a role in prostate carcinogenesis ([@bib6]; [@bib4]) and transcriptional upregulation of the AR target *ZWINT* has been associated with castration-resistant prostate cancer ([@bib43]). Altogether, these studies support the involvement of the genes in an aggressive prostate tumour phenotype.

In conclusion, pimonidazole-positive prostate cancer shows aggressive features, including activation of a transcriptional programme that promotes proliferation. The essential genes in this programme provide information on disease progression that is not correlated with the blood PSA level or covered by conventional clinical parameters such as Gleason score and by the *TMPRSS*-*ERG* fusion gene status. The gene signature might therefore be developed into a useful biomarker for identifying patients in need for intensified treatment, which possibly could include hypoxia targeting.
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![**Biobanking of punch biopsies from index tumour.** (**A**) Multiparametric MRI, left to right: T2W image, T2W image with inverted ADC-map overlaid and T2W image with DCE image overlaid. (**B**) Magnetic resonance imaging report based on the images in (**A**), indicating assumed index tumour foci (high -- red) and more uncertain areas (pink). (**C**) Punch biopsy taken from assumed index tumour focus. (**D**) Whole-mount HE section with cancer foci (black circles) and punch biopsy hole (arrow) from index tumour, correctly estimated by MRI. (**E**) Haematoxylin and eosin section of a punch biopsy, demonstrating \>75% malignant glands and \<50% stroma (original magnification × 100).](bjc2014604f1){#fig1}

![**Pimonidazole staining in relation to clinicopathological parameters.** (**A** and **B**) Histological section of index tumour biopsy from two different patients, showing low and high pimonidazole immunoscore of 0 and 5, respectively (original magnifications × 100). (**C** and **D**) Box plot of pimonidazole immunoscore at different clinical tumour stage (left; cT1, *n*=20; cT2, *n*=14; cT3, *n*=10) and lymph node status (right; negative, *n*=36; positive, *n*=8). Data were available for 44 patients. *P*-values from Mann--Whitney *U*-tests are displayed. In (**C**), *P*-value refers to cT3 *vs* cT1.](bjc2014604f2){#fig2}

![**Pimonidazole gene signature in relation to pimonidazole staining and tumour aggressiveness.** (**A**) Hierarchical clustering of patients (columns) based on the pimonidazole gene signature (rows). Red, green: high, low expression relative to median expression level, respectively; blue, yellow: pimonidazole-negative, -positive tumour, respectively; white: tumours without pimonidazole data. (**B** and **C**) Box plot of pimonidazole gene score at different clinical tumour stages (cT1, *n*=20; cT2, *n*=14; cT3, *n*=10) and lymph node status (negative, *n*=36; positive, *n*=8). Data were available for 44 patients. *P*-values from *χ*^2^-test (**A**) and *t*-tests (**B** and **C**) are displayed.](bjc2014604f3){#fig3}

![**Pimonidazole gene signature in relation to Ki67 staining.** (**A**) Ki67 labelling index *vs* pimonidazole gene score. Correlation coefficient (*r*) and *P*-value from Spearman\'s correlation analysis are shown. (**B**) Histological section showing Ki67 staining of the pimonidazole-positive tumour in [Figure 2B](#fig2){ref-type="fig"} with a Ki67 labelling index of 16.1% and gene score of 0.19 (original magnification × 100). Inset, pimonidazole staining of Ki67-positive malignant gland. The arrow points to the positive gland.](bjc2014604f4){#fig4}

![**Validation of the pimonidazole gene signature in two independent prostate cancer cohorts.** (**A**) Box plot of pimonidazole gene score for patients in the GSE32571 cohort with a Gleason score ⩽7a (*n*=32) and ⩾7b (*n*=27). *P*-value from *t*-test is displayed. (**B**) Kaplan--Meier curves for survival of 281 patients in the GSE16560 cohort. Number of patients and *P*-values from log-rank tests are displayed.](bjc2014604f5){#fig5}

###### Gene set enrichment in pimonidazole-positive tumours

  **Gene set**[a](#t1-fn2){ref-type="fn"}         **Phenotype**   **No. of genes**   ***P*****-value**
  ----------------------------------------------- --------------- ------------------ -------------------
  STARMANS_PROLIFERATION_SIGNATURE                Proliferation   104                0.013
  CHIANG_LIVER_CANCER_SUBCLASS_PROLIFERATION_UP   Proliferation   177                0.014
  GO_BASE_EXCISION_REPAIR                         DNA repair      17                 0.082
  KEGG_NON_HOMOLOGOUS_END_JOINING                 DNA repair      13                 0.088
  **HYPOXIA_UP_PROSTATE_CANCER_IN_VITRO**         Hypoxia         107                0.090
  BUFFA_HYPOXIA \_METAGENE                        Hypoxia         51                 0.10
  REACTOME_CELL_CYCLE_CHECKPOINTS                 Proliferation   110                0.11
  MENSE_HYPOXIA_UP                                Hypoxia         95                 0.11
  KEGG_HOMOLOGOUS_RECOMBINATION                   DNA repair      27                 0.11
  KEGG_MISMATCH_REPAIR                            DNA repair      23                 0.16
  KEGG_BASE_EXCISION_REPAIR                       DNA repair      32                 0.17
  HIF1_TARGETS                                    HIF1 pathway    273                0.20
  GO_DOUBLE_STRAND\_ BREAK_REPAIR                 DNA repair      23                 0.21
  TOUSTRUP_HYPOXIA\_*IN_VIVO*                     Hypoxia         15                 0.22
  AR_TARGETS                                      AR pathway      1115               0.24
  EUSTACE_HYPOXIA_CLASSIFIER                      Hypoxia         25                 0.27
  HALLE_HYPOXIA\_*IN_VIVO*                        Hypoxia         31                 0.30
  KEGG_NUCLEOTIDE_EXCISION_REPAIR                 DNA repair      44                 0.33
  KEGG_PROTEIN_PROCESSING_IN_ER                   Translation     163                0.33
  WINTER_HYPOXIA_UP                               Hypoxia         91                 0.42
  GO_NUCLEOTIDE_EXCISION_REPAIR                   DNA repair      20                 0.59

Abbreviation: GO=gene ontology.

The 5 first listed gene sets covered all significant biological processes from the GO analysis ([Supplementary Table S3](#sup1){ref-type="supplementary-material"}) and were used in construction of the hypoxia gene signature. The gene set in bold was created in the present work, the remaining gene sets were from the literature or the Molecular Signatures database.

###### Pimonidazole gene signature

                                                                                                                                                                           **Pimonidazole**   **Ki67**           
  -------------------------------------------------------- ------------------------------------ -------------------------------------------------------------------------- ------------------ ---------- ------- ---------
  **Proliferation gene sets[d](#t2-fn5){ref-type="fn"}**                                                                                                                                                         
  2630673                                                  ASF1B                                *Antisilencing function 1B histone chaperone*                              0.39               0.013      0.29    0.052
  6130441                                                  ASPM                                 *Abnormal spindle homolog, microcephaly associated (Drosophila)*           0.39               0.016      0.57    \<0.001
  1230682                                                  **BIRC5**                            *Baculoviral IAP repeat containing 5*                                      0.36               0.023      0.33    0.026
  6350348                                                  BUB3                                 *BUB3 mitotic checkpoint protein*                                          0.35               0.029      0.29    0.048
  2510639                                                  CENPE                                *Centromere protein E, 312 kDa*                                            0.45               0.004      0.26    0.078
  2120678                                                  CENPU                                *Centromere protein U*                                                     0.33               0.043      0.17    0.27
  6020746                                                  CMTM3                                *CKLF-like MARVEL transmembrane domain containing 3*                       0.49               0.002      0.20    0.18
  990725                                                   DONSON                               *Downstream neighbor of SON*                                               0.33               0.039      0.41    0.005
  5570296                                                  DTL                                  *Denticleless E3 ubiquitin protein ligase homolog (Drosophila)*            0.42               0.008      -0.07   0.65
  540053                                                   **FOXM1**                            *Forkhead box M1*                                                          0.39               0.014      0.31    0.034
  6520095                                                  G6PD                                 *Glucose-6-phosphate dehydrogenase*                                        0.38               0.018      -0.10   0.49
  3180367                                                  HJURP                                *Holliday junction recognition protein*                                    0.38               0.018      0.54    \<0.001
  6770408                                                  MCM2                                 *Minichromosome maintenance complex component 2*                           0.52               0.001      0.42    0.003
  1820176                                                  MEP1A                                *Meprin A, alpha (PABA peptide hydrolase)*                                 0.32               0.047      0.28    0.058
  3190768                                                  [MTMR2]{.ul}                         *Myotubularin-related protein 2*                                           0.32               0.049      -0.12   0.42
  5700373                                                  TRIP13                               *Thyroid hormone receptor interactor 13*                                   0.34               0.037      0.54    \<0.001
  650156                                                   [ZWINT]{.ul}                         *ZW10-interacting kinetochore protein*                                     0.33               0.042      −0.03   0.85
  **DNA repair gene sets[d](#t2-fn5){ref-type="fn"}**                                                                                                                                                            
  1990253                                                  TDG                                  *Thymine-DNA glycosylase*                                                  0.39               0.014      0.38    0.009
  3610750                                                  [UNG]{.ul}                           *Uracil-DNA glycosylase*                                                   0.36               0.024      0.32    0.033
  430100                                                   XRCC6                                *X-ray repair complementing defective repair in Chinese hamster cells 6*   0.40               0.011      0.43    0.003
  **Hypoxia gene set[d](#t2-fn5){ref-type="fn"}**                                                                                                                                                                
  5670465                                                  [ADM]{.ul}                           *Adrenomedullin*                                                           0.36               0.023      0.06    0.69
  3190148                                                  **DDIT4**                            *DNA-damage-inducible transcript 4*                                        0.44               0.005      0.34    0.02
  3610672                                                  **DSP**                              *Desmoplakin*                                                              0.35               0.03       0.23    0.13
  4640039                                                  FER1L4                               *Fer-1-like 4 (C. elegans), pseudogene*                                    0.42               0.008      0.05    0.72
  7320441                                                  **HILPDA**                           *Hypoxia-inducible lipid droplet-associated*                               0.37               0.021      0.03    0.87
  4220731                                                  **P4HA1**                            *Prolyl 4-hydroxylase, alpha polypeptide I*                                0.38               0.018      0.35    0.017
  1820424                                                  PGAM4                                *Phosphoglycerate mutase family member 4*                                  0.36               0.024      0.05    0.73
  2030093                                                  **PKM**[e](#t2-fn6){ref-type="fn"}   *Pyruvate kinase, muscle*                                                  0.42               0.009      0.22    0.14
  6840619                                                  RIMKLA                               *Ribosomal modification protein rimK-like family member A*                 0.39               0.014      0.40    0.006
  3930372                                                  RNASE4                               *Ribonuclease, RNase A family, 4*                                          0.46               0.004      0.10    0.50
  2140128                                                  **SCD**                              *Stearoyl-CoA desaturase (delta-9-desaturase)*                             0.37               0.022      0.04    0.77
  1190670                                                  **SPAG4**                            *Sperm-associated antigen 4*                                               0.32               0.047      0.14    0.37

Abbreviations: AR=androgen receptor; Corr=correlation coefficient; HIF1=hypoxia-inducible factor 1.

Illumina probe ID.

HUGO gene symbol and gene name.

Corr and *P*-value in Spearman\'s correlation analysis of pimonidazole immunoscore or Ki67 labelling index *vs* gene expression.

Genes in bold are known direct HIF1 targets, and underlined genes are known direct AR targets.

Also present in the proliferation gene sets.

###### Cox regression analysis of validation cohort[a](#t3-fn2){ref-type="fn"}

                                                        **Univariate analysis**   **Multivariate analysis**                                                    
  ---------------------------------------------------- ------------------------- --------------------------- ------------- --------------- ------------------- ------------
  **Factor**                                                 ***P*-value**            **Relative risk**       **95% CI**    ***P*-value**   **Relative risk**   **95% CI**
  Gleason score[b](#t3-fn3){ref-type="fn"}                      \<0.001                     1.84              1.63--2.09       \<0.001            1.62          1.41--1.87
  Cancer percentage[b](#t3-fn3){ref-type="fn"}                  \<0.001                     1.02              1.01--1.03        0.041             1.01          1.00--1.01
  Age[b](#t3-fn3){ref-type="fn"}                                \<0.001                     1.06              1.04--1.08       \<0.001            1.05          1.03--1.07
  TMPRSS-ERG status[c](#t3-fn4){ref-type="fn"}                  \<0.001                     2.32              1.65--3.28       (0.06)             1.44          0.99--2.10
  Pimonidazole gene score[b](#t3-fn3){ref-type="fn"}            \<0.001                     6.23              3.00--12.93       0.004             3.17          1.45--6.93

Abbreviation: CI=confidence interval.

The analysis was carried out on 267 patients, excluding 14 patients with missing values.

Continuous data were used.

Categorical data (0, 1) were used.
